Market Cap | 9.92M | P/E | - | EPS this Y | 42.10% | Ern Qtrly Grth | - |
Income | -5.85M | Forward P/E | 6.00 | EPS next Y | 106.20% | 50D Avg Chg | -16.00% |
Sales | 15.2M | PEG | -0.05 | EPS past 5Y | - | 200D Avg Chg | -44.00% |
Dividend | N/A | Price/Book | 0.59 | EPS next 5Y | 20.00% | 52W High Chg | -79.00% |
Recommedations | 2.00 | Quick Ratio | 0.89 | Shares Outstanding | 1.43M | 52W Low Chg | 16.00% |
Insider Own | 4.31% | ROA | -24.05% | Shares Float | 1.39M | Beta | 1.25 |
Inst Own | 10.10% | ROE | -38.01% | Shares Shorted/Prior | 5.24K/5.04K | Price | 0.36 |
Gross Margin | 39.60% | Profit Margin | -38.51% | Avg. Volume | 144,769 | Target Price | 19.00 |
Oper. Margin | -19.73% | Earnings Date | May 15 | Volume | 79,991 | Change | 2.83% |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
SANDBERG RICHARD A | Director Director | Jan 20 | Buy | 0.7765 | 20,000 | 15,530 | 40,846 | 01/23/23 |
Sabet Ahmed Zaki | Chief Operating Offi.. Chief Operating Officer | Jan 03 | Buy | 0.5974 | 750 | 448 | 6,863 | 01/03/23 |
DANIELI ILAN | Chief Executive Offi.. Chief Executive Officer | Jan 03 | Buy | 0.5974 | 16,500 | 9,857 | 57,046 | 01/03/23 |
Cohen David Seth | Director Director | Jun 10 | Sell | 3.99 | 69,962 | 279,148 | 692,092 | 03/01/22 |
Cohen David Seth | Director Director | May 27 | Sell | 3.99 | 40,178 | 160,310 | 762,054 | 03/01/22 |